trial

Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia

NCTId NCT00148590
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 24 (actual)
Sponsored by M. Schaefer, MD
Primary completion 2008-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2005-11
Primary completion
2008-06
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Memantine

Sponsors

M. Schaefer, MDLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Martin Schaefer, MDPrincipal Investigator

Sites

1 total
Berlin, Germany

Linked catalysts

1
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in P — primary completion2008-06

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE3
Primary Completion Date
2008-06
Status
TERMINATED
relationships
The graph out of here
drug
Memantine
drug
lead_sponsor
M. Schaefer, MD
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Martin Schaefer, MD
person